Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROADMAP: romidepsin with or without 3BNC117 to reduce HIV-1 reservoir
2015-005238-23Phase 2Terminated
- Sponsor
- The Rockefeller University
- Start
- Aug 2016
- Modality
- Small Molecules, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in human immunodeficiency virus infection (HIV) comparing Romidepsin alone with Romidepsin + 3BNC117 (2 arms). Primary endpoint: Time to viral rebound or ART reinitiation during ATI. Started Aug 2016; status: terminated.
02
Drugs
romidepsinTeropavimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-005238-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005238-23.